NCT05881720 is a Phase 4 clinical trial of Sacubitril / Valsartan Oral Tablet in Heart Failure, sponsored by Damanhour University.

Who is sponsoring NCT05881720?

NCT05881720 is sponsored by Damanhour University.

What drugs are being tested in NCT05881720?

Interventions in NCT05881720: Sacubitril / Valsartan Oral Tablet, Valsartan 80 mg.

What condition does NCT05881720 study?

NCT05881720 studies Heart Failure.

Is NCT05881720 still recruiting?

NCT05881720 is currently completed. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05881720

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Completed Phase 4 Last updated 27 June 2023

What this trial tests

Phase 4 trial testing Sacubitril / Valsartan Oral Tablet in Heart Failure in 80 participants. Completed in 19 June 2023.

Timeline

1 January 2022

Primary endpoint
18 June 2023

19 June 2023

Quick facts

Lead sponsor	Damanhour University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	1 January 2022
Primary completion	18 June 2023
Estimated completion	19 June 2023
Sites	1 location across Egypt

Drugs / interventions tested

Sacubitril / Valsartan Oral Tablet — full drug profile →
Valsartan 80 mg — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Damanhour University

Who can join

Adults 35 to 80, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study was to identify potential prognostic factors of sacubitril/valsartan vs Valsartan treatment response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sacubitril / Valsartan Oral Tablet

Trials testing the same drug.

NCT06704633 — Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania · Phase 4 · not yet recruiting
NCT05117736 — ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure · NA · terminated
NCT04218435 — Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients · completed

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Damanhour University trials

Trials by the same sponsor.

NCT07307911 — Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy · Phase 2 · completed
NCT07341893 — Sacubitril-valsartan in Patients With Heart Failure. · NA · recruiting
NCT07063628 — Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity · completed
NCT06849388 — Effect of HeartMath Intervention on Stress, Emotional Vitality and Sense of Coherence · NA · recruiting
NCT07179302 — Pre- and Post-TAVI Patient Assessment: Advancing Outcome Precision in Aortic Valve Therapy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05881720 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Damanhour University
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05881720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing